This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goldstein, E. J. C. Articles by Fernandez, H. Search for Related Content PubMed PubMed Citation Articles by Goldstein, E. J. C. Articles by Fernandez, H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2003, p. 1963-1967, Vol. 47, No. 6
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.6.1963-1967.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of Telithromycin and 10 Oral Agents against Aerobic and Anaerobic Pathogens Isolated from Antral Puncture Specimens from Patients with Sinusitis

R. M. Alden Research Laboratory, Santa Monica, California 90404,¹ University of California at Los Angeles School of Medicine, Los Angeles, California 90073²

Received 17 October 2002/ Returned for modification 21 February 2003/ Accepted 10 March 2003

A study of the comparative in vitro activity of telithromycin, a new ketolide, against 155 aerobic and 171 anaerobic antral sinus puncture isolates showed it to be active against a broad range of sinus pathogens. All pneumococci, including erythromycin-resistant strains, were susceptible to telithromycin at 0.5 µg/ml; all Haemophilus influenzae and Eikenella corrodens strains were inhibited by 4 µg of telithromycin/ml; all Moraxella spp. and beta-lactamase-producing Prevotella species strains were inhibited by 0.25 and 0.5 µg of telithromycin/ml, respectively. Among all anaerobes tested, 94% (160 of 171 strains) were susceptible to 4 µg of telithromycin/ml; however, 8 of 17 (47%) Fusobacterium strains, 2 Veillonella strains, and 1 Peptostreptococcus micros strain required >4 µg of telithromycin/ml for inhibition. Telithromycin may offer a therapeutic alternative for sinus infections, including those due to erythromycin-resistant pneumococci.

This article has been cited by other articles:

• Brook, I., Hausfeld, J. N. (2005). Recovery of Interfering Bacteria in the Nasopharynx following Antimicrobial Therapy of Acute Maxillary Sinusitis with Telithromycin or Amoxicillin-Clavulanate. Antimicrob. Agents Chemother. 49: 4793-4794 [Abstract] [Full Text]  
• Chollet, R., Chevalier, J., Bryskier, A., Pages, J.-M. (2004). The AcrAB-TolC Pump Is Involved in Macrolide Resistance but Not in Telithromycin Efflux in Enterobacter aerogenes and Escherichia coli. Antimicrob. Agents Chemother. 48: 3621-3624 [Abstract] [Full Text]